BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Cancer Platforms, Reports Narrowed Loss for Q4 2024

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, reported a reduced net loss of $4.1 million for Q4 2024, down from $8.2 million the prior year. The company highlighted significant progress across its three oncology platforms, including the IND filing for CLD-201 targeting solid tumors and continued clinical development of CLD-101 for high-grade glioma. Preclinical data on its CLD-400 platform showed complete tumor eradication in some models. Research and development expenses fell to $1.8 million from $4.0 million year over year, while full-year net loss narrowed to $23.8 million. Calidi ended 2024 with $9.6 million in cash. 

To view the full press release, visit https://ibn.fm/MrGL3 

About Calidi Biotherapeutics 

Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. 

For more information, please visit www.calidibio.com 

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN